Recombinant proteins are an important tool for research and therapeutic applications. Therapeutic proteins have been delivered to several cell types and tissues and might be used to improve the outcome of the cell transplantation. Recombinant proteins are propagated in bacteria, which will contaminate them with the lypopolysacharide endotoxin found in the outer bacterial membrane. Endotoxin could interfere with in vitro biological assays and is the major pathological factor, which must be removed or inactivated before in vivo administration. Here we describe a one-step protocol in which the endotoxin activity on recombinant proteins is remarkably reduced by transient exposure to acidic conditions. Maximum endotoxin deactivation occurs at acidic pH below their respective isoelectric point (pI). This method does not require additional protein purification or separation of the protein from the endotoxin fraction. The endotoxin level was measured both in vitro and in vivo. For in vitro assessment we have utilized Limulus Amebocyte Lysate method for in vivo the pyrogenic test. We have tested the above-mentioned method with five different recombinant proteins, including a monoclonal antibody clone 5c8 against CD154 produced by hybridomas. More than 99% of endotoxin was deactivated in all of the proteins; the recovery of the protein after deactivation varied between maximum 72.9% and minimum 46.8%. The anti-CD154 clone 5c8 activity remained unchanged as verified by the measurement of binding capability to activated lymphocytes. Furthermore, the effectiveness of this method was not significantly altered by urea, commonly used in protein purification. This procedure provides a simple and cost-efficient way to reduce the endotoxin activity in antibodies and recombinant proteins.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461865 | PMC |
http://dx.doi.org/10.3727/096368910X500643 | DOI Listing |
J Infect Dev Ctries
December 2024
Special Infectious Agents Unit, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia.
Introduction: Alkhumra hemorrhagic fever virus (AHFV) is a newly discovered virus in the Flaviviridae family. It was discovered in 1995 among animal handlers in Saudi Arabia. AHFV spreads through close contact with infected animals and tick bites.
View Article and Find Full Text PDFInt Ophthalmol
January 2025
Beyoglu Eye Training and Research Hospital, University of Health Sciences, Bereketzade Camii Sk. No:2 Beyoğlu, 34421, Istanbul, Turkey.
Background: To evaluate the efficacy and safety of intravitreal injections of 4 mg (high dose) of aflibercept in treatment-naive patients with neovascular AMD(nAMD) with treat and extend(TREX) dosing regimens, and to determine the frequency of injections.
Methods: In this interventional, retrospective study a total of 15 eyes of 14 patients (eight female and 9 male) with nAMD were included. All patients were examined and OCT imaging was performed at the time of initial presentation, on the day of each injection and at subsequent follow-up visits.
Front Cell Infect Microbiol
January 2025
The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Objective: To establish a rapid detection method for canine using recombinase-aided amplification (RAA) technology.
Methods: The outer membrane protein 25 gene fragment (Omp25) of canis was targeted. Primers and fluorescent probes were designed and synthesized, and recombinant plasmids were constructed as standards.
Front Immunol
January 2025
RNAimmune, Inc., Germantown, MD, United States.
Background: The unrelenting emergence of SARS-CoV-2 variants has significantly challenged the efficacy of existing COVID-19 vaccines. Enhancing the stability and immunogenicity of the spike protein is critical for improving vaccine performance and addressing variant-driven immune evasion.
Methods: We developed an mRNA-based vaccine, RV-1730, encoding the Delta variant spike protein with the S6P mutation to enhance stability and immunogenicity.
ACS Omega
January 2025
Department of Chemical Engineering, University of Virginia, Charlottesville, Virginia 22903, United States.
Biomineralization is a green synthesis route for a variety of metal nanoparticles. Silicatein is a biomineralization protein originally found in marine sponge that converts inorganic precursors to metal oxide nanoparticles. In this work, we investigate the popular catalytic triad hypothesis and implement directed evolution with the aim to improve the solubility and kinetics of silicatein to enable increased nanoparticle synthesis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!